Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Open accessThe DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Abstract
Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiological studies of mood disorders, and most therapeutics target these systems. However, there is growing evidence that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiology as well as the efficacy of glutamatergic agents in mood disorders. We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This could lead to astrocyte/microglia imbalance, glutamatergic overproduction and excitotoxic neuronal damage (Sanacora et al., 2008) with impact on synapse functionality.”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, increased glutamate levels has been associated with mechanisms involved in stress and depression, such as neuro-inflammatory process, decreased levels of neurotrophic factors, diminished neurogenesis, and neuroplasticity impairment [116,117].”
From P2X7 Receptor Signaling in Stress and Depression (2019) · cites this paper as [117]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, rapidly acting antidepressants were discovered in the glutamatergic system (Berman et al., 2000;Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Several classes of antidepressants as well as SSRIs are known to exert action on the glutamate system by influencing NMDA or AMPA receptor transcription (Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Glia also play an important role in regulating the synthesis and reuptake of glutamate and thereby influence synaptic function and morphology16,17.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Although most patients with mood disorders receive some benefit from available treatment”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationEvidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · cited 1×
“, and is approved for the treatment of moderate to severe Alzheimer's disease, in which it has been shown to enhance cognition and minimize clinical deterioration in patients with Alzheimer's disease, vascular dementia or mixed dementi”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Research works printed but not linked: 1
- Preskorn, S. et al. A placebo-controlled trial of the NR2B subunit specific NMDA antagonist CP-101,606 plus paroxetine for treatment resistant depression (TRD). Annual Conference of the American Psychological Association (San Francisco, California) 154 (2007).
Cited by
Items 301–400 of 1,000
Open-Label Uridine for Treatment of Depressed Adolescents with Bipolar Disorder
Kondo, D. G., Sung, Y., Hellem, T., Delmastro, K. K., Jeong, E., Kim, N., Shi, X., & Renshaw, P. F. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0054 · Cited by 47
VGLUTs in Peripheral Neurons and the Spinal Cord: Time for a Review
Brumovsky, P. R. (2013) · ISRN Neurology · doi:10.1155/2013/829753 · Cited by 43
Reduction in the latency of action of antidepressants by 17 β-estradiol in the forced swimming test
Estrada-Camarena, E. M., Vega‐Rivera, N. M., Berlanga, C., & Fernández‐Guasti, A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1291-8 · Cited by 47
Mehta, M. A., Schmechtig, A., Kotoula, V., McColm, J., Jackson, K. A., Brittain, C., Tauscher‐Wisniewski, S., Kinon, B. J., Morrison, P. D., Pollak, T. A., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4877-9 · Cited by 47
Kawasaki, T., Ago, Y., Yano, K., Araki, R., Washida, Y., Onoe, H., Chaki, S., Nakazato, A., Hashimoto, H., Baba, A., et al. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.009 · Cited by 46
Mayhew, J., Beart, P. M., & Walker, F. R. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12273 · Cited by 46
Lithium – therapeutic tool endowed with multiple beneficiary effects caused by multiple mechanisms
Vošahlíková, M., & Svoboda, P. (2016) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2017-001 · Cited by 46
Taylor, M. J., Selvaraj, S., Norbury, R., Jezzard, P., & Cowen, P. J. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.02.022 · Cited by 45
Millan, M. J., Rivet, J.-M., & Gobert, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116672342 · Cited by 45
Ostadhadi, S., Ahangari, M. M., Nikoui, V., Norouzi‐Javidan, A., Zolfaghari, S., Jazaeri, F., Chamanara, M., Akbarian, R., & Dehpour, A. R. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.05.035 · Cited by 45
Weigend, S., Holst, S. C., Treyer, V., Tuura, R., Meier, J., Ametamey, S. M., Buck, A., & Landolt, H. (2019) · SLEEP · doi:10.1093/sleep/zsz161 · Cited by 45
Cannabidiol and the Canonical WNT/β-Catenin Pathway in Glaucoma
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073798 · Cited by 45
Domin, H., Szewczyk, B., Woźniak, M., Wawrzak-Wleciał, A., & Śmiałowska, M. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.019 · Cited by 45
A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression
Zheng, W., Zhou, Y.-L., Liu, W.-J., Wang, C.-Y., Zhan, Y.-N., Lan, X.-F., Zhang, B., & Ning, Y.-P. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.06.020 · Cited by 44
Antistress properties of antidepressant drugs and their clinical implications
Calabrese, F., Molteni, R., & Riva, M. A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.05.007 · Cited by 44
Ostadhadi, S., Khan, M. I., Norouzi‐Javidan, A., & Dehpour, A. R. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.04.026 · Cited by 44
Beyond Ketamine: New Approaches to the Development of Safer Antidepressants
Chaki, S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170221101054 · Cited by 40
Chaperone Sigma1R and Antidepressant Effect
Воронин, М. В., Vakhitova, Y. V., & Середенин, С. Б. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197088 · Cited by 44
Amare, A. T., Thalamuthu, A., Schubert, K. O., Fullerton, J. M., Ahmed, M. B., Hartmann, S., Papiol, S., Heilbronner, U., Degenhardt, F., Ayele, F. T., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02149-1 · Cited by 44
Ketamine—A Narrative Review of Its Uses in Medicine
Radvansky, B. M., Puri, S., Sifonios, A. N., Eloy, J. D., & Le, V. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000257 · Cited by 44
Zhu, X., Ye, G., Wang, Z., Luo, J., & Hao, X. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.12.070 · Cited by 43
Zomkowski, A. D. E., Engel, D. F., Cunha, M. P., Gabilan, N. H., & Rodrigues, A. L. S. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.09.011 · Cited by 43
Tao, C., Zhang, G.-W., Sun, W.-J., Huang, J. J., Zhang, L. I., & Tao, H. W. (2024) · Nature Communications · doi:10.1038/s41467-024-52727-2 · Cited by 42
From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation
Krasner, H., Ong, C. V., Hewitt, P., & Vida, T. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073219 · Cited by 42
Amidfar, M., Khiabany, M., Kohi, A., Salardini, E., Arbabi, M., Roohi Azizi, M., Zarrindast, M.-R., Mohammadinejad, P., Zeinoddini, A., & Akhondzadeh, S. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12469 · Cited by 40
Woltering, T. J., Wichmann, J., Goetschi, E., Knoflach, F., Ballard, T. M., Huwyler, J., & Gatti, S. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.125 · Cited by 42
Li, R., Ma, Z., Yu, J., He, Y., & Li, J. (2014) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2014.02.013 · Cited by 42
Właź, P., Regina, K., Właź, A., Szumiło, M., Wróbel, A., Gabriel, N., & Poleszak, E. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70716-2 · Cited by 42
Andreasen, J. T., Gynther, M., Rygaard, A., Bøgelund, T., Nielsen, S. D., Clausen, R. P., Mogensen, J., & Pickering, D. S. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.04.045 · Cited by 42
Wu, X., Chen, B., Di, Z., Jiang, S., Xu, H., Shi, M., Hu, R., Sun, S., Song, Z., Liu, J., et al. (2022) · BMC Neuroscience · doi:10.1186/s12868-022-00746-4 · Cited by 41
Ostadhadi, S., Khan, M. I., Norouzi‐Javidan, A., Chamanara, M., Jazaeri, F., Zolfaghari, S., & Dehpour, A. R. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.004 · Cited by 41
Ostadhadi, S., Norouzi‐Javidan, A., Chamanara, M., Akbarian, R., Imran-Khan, M., Ghasemi, M., & Dehpour, A. R. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.07.016 · Cited by 41
Bartoli, F., Cavaleri, D., Bachi, B., Moretti, F., Riboldi, I., Crocamo, C., & Carrà, G. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.09.018 · Cited by 37
Hippocampal CA3 calcineurin activity participates in depressive‐like behavior in rats
Zhu, W., Shi, H., Wang, S., Wu, P., Ding, Z., & Lu, L. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07285.x · Cited by 34
Takahashi, K., Murasawa, H., Yamaguchi, K., Yamada, M., Nakatani, A., Yoshida, M., Iwai, T., Inagaki, M., Yamada, M., & Saitoh, A. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.07.002 · Cited by 41
Abelaira, H. M., Réus, G. Z., Ignácio, Z. M., dos Santos, M. A. B., de Moura, A. B., Matos, D., Demo, J. P., da Silva, J. B. I., Michels, M., Abatti, M. R., et al. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.12.002 · Cited by 40
Triple Reuptake Inhibitors (“Broad Spectrum” Antidepressants)
Skolnick, P., & Basile, A. S. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707780363285 · Cited by 40
Sakhaee, E., Ostadhadi, S., Khan, M. I., Yousefi, F., Norouzi‐Javidan, A., Akbarian, R., Chamanara, M., Zolfaghari, S., & Dehpour, A. R. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.073 · Cited by 40
Mishra, P. K., Kumar, A., Behar, K. L., & Patel, A. B. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14544 · Cited by 39
“Therefore, targeting the glutamatergic system may be a good strategy for the treatment of depression (Sanacora et al. 2008; Murrough et al. 2017).”
BackgroundStructure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid
Costa, B. M., Irvine, M. W., Fang, G., Eaves, R. J., Mayo-Martin, M. B., Laube, B., Jane, D. E., & Monaghan, D. T. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.11.019 · Cited by 39
Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology
Data-Franco, J., Singh, A., Popovic, D., Ashton, M., Berk, M., Vieta, E., Figueira, M. L., & Dean, O. M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.09.004 · Cited by 38
Long-lasting antidepressant-like activity of the GPR39 zinc receptor agonist TC-G 1008
Starowicz, G., Jarosz, M., Frąckiewicz, E., Grzechnik, N., Ostachowicz, B., Nowak, G., & Młyniec, K. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.003 · Cited by 38
Physical Activity Reduces Clinical Symptoms and Restores Neuroplasticity in Major Depression
Brüchle, W., Schwarzer, C., Berns, C., Scho, S., Schneefeld, J., Koester, D., Schack, T., Schneider, U., & Rosenkranz, K. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.660642 · Cited by 38
Liu, C. Y., Jiang, X. X., Zhu, Y. H., & Wei, D. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.08.010 · Cited by 38
Iyo, A. H., Feyissa, A. M., Chandran, A., Austin, M. C., Regunathan, S., & Karolewicz, B. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.06.023 · Cited by 37
Could dietary glutamate play a role in psychiatric distress?
Kraal, A., Arvanitis, N. R., Jaeger, A., & Ellingrod, V. (2019) · Neuropsychobiology · doi:10.1159/000496294 · Cited by 28
Elevated cortical glutamate in young people at increased familial risk of depression
Taylor, M. J., Mannie, Z. N., Norbury, R., Near, J., & Cowen, P. J. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001094 · Cited by 37
Santarelli, S., Wagner, K. V., Labermaier, C., Uribe, A., Dournes, C., Balsevich, G., Hartmann, J., Masana, M., Holsboer, F., Chen, A., et al. (2015) · Stress · doi:10.3109/10253890.2015.1105211 · Cited by 37
Anticevic, A., Schleifer, C., & Cho, Y. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.4/aanticevic · Cited by 37
Amidfar, M., Réus, G. Z., Quevedo, J., Kim, Y., & Arbabi, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.11.003 · Cited by 36
Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction
Wilson, C., Li, S., Hannan, A. J., & Renoir, T. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107998 · Cited by 36
Kangas, E. S., Vuoriainen, E., Lindeman, S. M., & Astikainen, P. (2022) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2022.07.003 · Cited by 36
Bentea, E., Demuyser, T., Liefferinge, J. V., Albertini, G., Deneyer, L., Nys, J., Merckx, E., Michotte, Y. M., Sato, H., Arckens, L., et al. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.01.010 · Cited by 36
Luo, D., Ma, R., Wu, Y., Zhang, X., Liu, Y., Wang, L., & Fu, W. (2017) · Medical Science Monitor · doi:10.12659/msm.902549 · Cited by 35
Brain glutamatergic characteristics of pediatric offspring of parents with bipolar disorder
Singh, M. K., Spielman, D. M., Adleman, N. E., Alegría, D., Howe, M. E., Reiss, A. L., & Chang, K. (2010) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2010.01.003 · Cited by 35
Khan, M. I., Ostadhadi, S., Zolfaghari, S., Mehr, S. E., Hassanzadeh, G., & Dehpour, A. R. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.12.006 · Cited by 35
Implication of NMDA-NO pathway in the antidepressant-like effect of ellagic acid in male mice
Lorigooini, Z., Salimi, N., Soltani, A., & Amini-Khoei, H. (2019) · Neuropeptides · doi:10.1016/j.npep.2019.04.003 · Cited by 35
Gruenbaum, B. F., Kutz, R., Zlotnik, A. A., & Boyko, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320903951 · Cited by 35
Mismatch negativity indices and functional outcomes in unipolar and bipolar depression
Kim, S., Baek, J. H., Shim, S.-H., Kwon, Y., Lee, H.-Y., Yoo, J. H., & Kim, J. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-69776-4 · Cited by 35
Bellia, F., Vismara, M. E. M., Annunzi, E., Cifani, C., Benatti, B., Dell’Osso, B. M., & D’Addario, C. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.10.040 · Cited by 35
Hsu, L.-C., Ko, Y.-J., Cheng, H., Chang, C.-W., Lin, Y., Cheng, Y., Hsieh, M., & Peng, W. H. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/497302 · Cited by 35
Atagün, M. İ., Şıkoğlu, E. M., Can, S. S., Karakaş-Uğurlu, G., Ulusoy-Kaymak, S., Çayköylü, A., Algın, O., Phillips, M. L., Moore, C. M., & Öngür, D. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.012 · Cited by 35
Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors
Imbesi, M., Uz, T., Manev, R., Sharma, R. P., & Manev, H. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.10.006 · Cited by 34
Hermens, D. F., Chitty, K. M., Lee, R. S., Tickell, A., Haber, P. S., Naismith, S. L., Hickie, I. B., & Lagopoulos, J. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.07.009 · Cited by 34
Mishra, P. K., Adusumilli, M., Deolal, P., Mason, G. F., Kumar, A., & Patel, A. B. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104750 · Cited by 34
Gonsalves, M. A., White, T. L., Barredo, J., Fukuda, A. M., Joyce, H. E., Harris, A. D., & Carpenter, L. L. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103049 · Cited by 34
Langhein, M., Seitz‐Holland, J., Lyall, A. E., Pasternak, O., Chunga, N., Karayumak, S. C., Kubicki, A., Mulert, C., Espinoza, R. T., Narr, K. L., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.043 · Cited by 34
Linck, V. M., Costa-Campos, L., Pilz, L. K., Garcia, C. R. L., & Elisabetsky, E. (2012) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283512c3a · Cited by 34
Effect of Valproic Acid Through Regulation of NMDA Receptor–ERK Signaling in Sleep Deprivation Rats
Park, H. J., Kang, W. S., Paik, J., & Kim, J. W. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9673-5 · Cited by 34
Ning, L., Zhang, T., Chu, J., Qu, N., Li, L., Fang, Y., Shi, Y., Zeng, P. H., Cai, E., Wang, X., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0352-y · Cited by 34
Li, B., Zhang, S., Li, M., Zhang, H., Hertz, L., & Peng, L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.004 · Cited by 33
“Other glutamate receptors are also involved in the pathophysiology of bipolar disorder and are targets of anti-bipolar drugs (Sanacora et al., 2008).”
Liu, S., Li, Y., Shi, Y., Rao, Z., Zhang, Y., Zhang, Y., Wang, T., Kong, H., Zhu, S., Zhu, D., et al. (2025) · Psychological Medicine · doi:10.1017/s003329172510072x · Cited by 33
Inta, D., Trusel, M., Riva, M. A., Sprengel, R., & Gass, P. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990319 · Cited by 33
Study on antidepressant activity of chiisanoside in mice
Bian, X., Liu, X., Liu, J., Zhao, Y. H., Li, H., Cai, E., Li, P., & Gao, Y. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.02.007 · Cited by 33
Kumar, A., Dogra, S., Sona, C., Umrao, D., Rashid, M., Singh, S. K., Wahajuddin, M., & Yadav, P. N. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.11.007 · Cited by 33
Small Molecule Screening Identifies Regulators of the Transcription Factor ΔFosB
Wang, Y., Cesena, T. I., Ohnishi, Y., Burger-Caplan, R., Lam, V., Kirchhoff, P. D., Larsen, S. D., Larsen, M. J., Nestler, E. J., & Rudenko, G. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn3000235 · Cited by 30
Glutamate system as target for development of novel antidepressants
Catena-Dell’Osso, M., Fagiolini, A. M., Rotella, F., Baroni, S., & Marazziti, D. (2013) · CNS Spectrums · doi:10.1017/s1092852912000971 · Cited by 33
Reuillon, T. D., Ward, S. E., & Beswick, P. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160627114507 · Cited by 33
RNA Editing and Modifications in Mood Disorders
Barbon, A., & Magri, C. (2020) · Genes · doi:10.3390/genes11080872 · Cited by 33
Zhang, Q., Bai, Z.-L., Gong, Y., Liu, X., Dai, X.-Q., Wang, S., & Liu, F. (2015) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2015.03.004 · Cited by 33
Wang, X., Yang, Y., Zhou, X., Wu, J., Li, J., Jiang, X. L., Qu, Q., Ou, C., Liu, L., & Zhou, S. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.04.046 · Cited by 33
Nava, N., Treccani, G., Liebenberg, N., Chen, F., Popoli, M., Wegener, G., & Nyengaard, J. R. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu085 · Cited by 32
“By limiting the number of glutamate vesicles available for release and the number of excitatory synapses as potential glutamate release sites, DMI may help prevent FS stress-induced boosting of the mPFC glutamate system and subsequent hyperglutamate–induced noxious effects (Sanacora et al., 2008; Popoli et al., 2012).”
BackgroundRapid antidepressant effects: moving right along
Martinowich, K., Jimenez, D. V., Zarate, C. A., & Manji, H. K. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.55 · Cited by 32
Self-citationSpecies-conserved reconfigurations of brain network topology induced by ketamine
Becker, R., Braun, U., Schwarz, A. J., Gass, N., Schweiger, J. I., Weber‐Fahr, W., Schenker, E., Spedding, M., von Hohenberg, C. C., Risterucci, C., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.53 · Cited by 32
Neuronal Plasticity: Neuronal Organization is Associated with Neurological Disorders
Dhuriya, Y. K., & Sharma, D. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01555-2 · Cited by 32
Neurotoxicity in Gulf War Illness and the potential role of glutamate
Joyce, M. R., & Holton, K. F. (2020) · NeuroToxicology · doi:10.1016/j.neuro.2020.06.008 · Cited by 32
Impact of nonalcoholic fatty liver disease-related metabolic state on depression
Ntona, S., Papaefthymiou, A., Kountouras, J., Gialamprinou, D., Kotronis, G., Boziki, M. K., Pοlyzos, S. A., Tzitiridou‐Chatzopoulou, M., Chatzopoulos, D., Thavayogarajah, T., et al. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105484 · Cited by 32
Hellem, T., Shi, X., Latendresse, G., & Renshaw, P. F. (2015) · Journal of the American Psychiatric Nurses Association · doi:10.1177/1078390315598606 · Cited by 32
Mood stabilizers increase prepulse inhibition in DBA/2NCrl mice
Flood, D. G., Choinski, M., Marino, M. J., & Ga̧sior, M. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1547-y · Cited by 32
Ishiwata, S., Hattori, K., Sasayama, D., Teraishi, T., Miyakawa, T., Yokota, Y., Matsumura, R., Nishikawa, T., & Kunugi, H. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.035 · Cited by 31
Early life stress and glutamate neurotransmission in major depressive disorder
Averill, L. A., Abdallah, C. G., Fenton, L. R., Fasula, M. K., Jiang, L., Rothman, D. L., Mason, G. F., & Sanacora, G. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.03.015 · Cited by 31
Self-citationNaspolini, N. F., Rieg, C. E. H., Cenci, V. H., Cattani, D., & Zamoner, A. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.05.010 · Cited by 31
Chen, K.-T., Wu, C.-H., Tsai, M., Wu, Y.-C., Jou, M., Huang, C., & Wei, I. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.004 · Cited by 31
Mohseni, G., Ostadhadi, S., Imran-Khan, M., Norouzi‐Javidan, A., Zolfaghari, S., Haddadi, N., & Dehpour, A. R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.119 · Cited by 31
Balasubramanian, D., Deng, A. X., Doudney, K., Hampton, M. B., & Kennedy, M. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.06.018 · Cited by 31
Gigliucci, V., Gormley, S., Gibney, S. M., Rouine, J., Kerskens, C., Connor, T. J., & Harkin, A. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.05.003 · Cited by 30
Machado‐Vieira, R., & Zarate, C. A. (2011) · Depression and Anxiety · doi:10.1002/da.20800 · Cited by 30
Self-citationIno, H., Honda, S., Yamada, K., Horita, N., Tsugawa, S., Yoshida, K., Noda, Y., Meyer, J. H., Mimura, M., Nakajima, S., et al. (2022) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2022.09.017 · Cited by 30
Gruenbaum, B. F., Schonwald, A., Boyko, M., & Zlotnik, A. A. (2024) · Cells · doi:10.3390/cells13141228 · Cited by 30
Li, B., Dong, L., Fu, H. Q., Wang, B., Hertz, L., & Peng, L. (2011) · Cell Calcium · doi:10.1016/j.ceca.2011.05.001 · Cited by 30
Metadata
- Authors
- Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K.
- Affiliations
- Yale University (US)
- National Institutes of Health (US)
- Corresponding author
- Manji, Husseini K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-05
- Volume
- 7
- Issue
- 5
- Pages
- 426-437
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC2715836
- OpenAlex
- W2074907255
- Cited by
- 894
- References
- 186
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 33 · 2023: 44 · 2022: 36 · 2021: 44 · 2020: 56 · 2019: 43 · 2018: 40 · 2017: 50 · 2016: 63 · 2015: 70 · 2014: 59 · 2013: 56 · 2012: 68
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (K02MH076222, Z01MH002828, Z01MH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- glutamatergic system, mood disorders, antidepressants, neuroplasticity, glutamatergic agents, monoaminergic systems, rapid-acting antidepressants, drug development
- MeSH terms
- Animals, Glutamates, Humans, Psychotropic Drugs, Excitatory Amino Acid Antagonists, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.